Testing of Injectables & Parenterals: Sterility, Particulates & Container Integrity
Aerospace corrosion testing per MIL-STD-810 evaluating alloy and coating protection performanceWhat Are Injectables and Parenterals?
Parenteral drug products are those administered by routes other than the gastrointestinal tract—primarily by injection or infusion. They include small-volume parenterals (SVPs) such as prefilled syringes and vials, large-volume parenterals (LVPs) such as IV bags, and implantable drug delivery systems. Because parenterals bypass the body’s natural barriers, they carry the highest safety requirements of any drug delivery route.
The materials used in parenteral primary packaging—glass vials, rubber stoppers, polymer syringes, stainless steel needles, and adhesive labels—must be extensively tested to ensure they do not compromise drug safety, efficacy, or patient safety. The pharmaceutical, biotechnology, and medical device industries rely on rigorous material testing protocols to meet FDA, EMA, and USP/EP standards.
Why Material Testing Is Critical for Parenterals
Extractables and Leachables (E&L)
Compounds that migrate from container closure components into the drug product can be toxic, immunogenic, or chemically incompatible with the API. Leachable testing for parenterals follows ICH Q3E, USP <661>, USP <1661>, and ISO 10993 frameworks.
Particulate Contamination
Parenteral products must be essentially free of visible and sub-visible particles. Materials used in container closures and delivery devices must not shed particles during processing, storage, or use. USP <787>, <788>, and <789> define limits for sub-visible particulate matter.
Sterility and Biocompatibility
All materials in contact with parenteral formulations must be sterilizable without compromising material integrity or generating degradation products. ISO 10993 biocompatibility assessments are required for components in contact with blood or tissue.
Key Material Testing Categories for Parenterals
Glass Container Testing
Type I borosilicate glass is the standard for most parenteral vials. Testing includes:
- Hydrolytic resistance (USP <660>, EP 3.2.1) — measures alkali release from glass surfaces in contact with water
- Chemical resistance — assesses resistance to specific drug formulations
- Delamination risk — evaluates the tendency of glass to shed glass flakes into the product (a critical safety concern for biologics)
- Dimensional and cosmetic inspection
Rubber Closure (Stopper) Testing
Rubber stoppers are among the richest sources of extractables in parenteral packaging. Testing includes:
- Exhaustive extraction (USP <381>) — identifies rubber-derived extractables (nitrosamines, vulcanisation residues, antioxidants)
- Fragmentation testing — evaluates stopper coring and particle generation during needle penetration
- Self-sealing — verifies stopper resealing after needle withdrawal
- Chemical compatibility — stopper-formulation interaction studies
Polymer Syringe and Cartridge Testing
Cyclic olefin polymer (COP) and cyclic olefin copolymer (COC) syringes offer superior extractables profiles compared to conventional polypropylene. Testing includes:
- Extractables profiling (GC-MS, LC-MS, ICP-MS)
- Mechanical performance (break-loose force, glide force)
- Dimensional stability after sterilisation
Needle and Metal Component Testing
Stainless steel needles are evaluated for:
- Elemental impurities (ICP-MS)
- Passivation layer integrity (corrosion resistance)
- Dimensional and sharpness verification (ISO 7864)
Regulatory Standards for Parenteral Material Testing
Standard | Scope |
USP <661> / <1661> | Plastic and glass packaging systems |
USP <381> | Elastomeric closures for injectables |
USP <787> / <788> | Sub-visible particulate matter |
ICH Q3E | Extractables and leachables |
ISO 10993 | Biocompatibility of medical devices |
EP 3.2.1 | Glass containers for pharmaceutical use |
Conclusion
Parenteral drug products demand the highest level of material integrity due to their direct administration into the body. Rigorous material testing—covering extractables and leachables, particulate contamination, sterility, and compatibility—is essential to ensure patient safety and drug stability. By adhering to stringent regulatory standards and employing comprehensive testing strategies, manufacturers can deliver safe, effective, and reliable injectable therapies across pharmaceutical and biotechnology applications.
Why Choose Infinita Lab for Injectable and Parenteral Material Testing?
Infinita Lab offers comprehensive parenteral material testing services operated under cGMP standards. Our accredited laboratory network provides full E&L programs, glass delamination studies, stopper characterisation, and biocompatibility testing with expert regulatory support.
Looking for a trusted partner to achieve your research goals? Schedule a meeting with us, send us a request, or call us at (888) 878-3090 to learn more about our services and how we can support you. Request a Quote
Frequently Asked Questions (FAQs)
What is glass delamination and why is it a concern for parenterals? Glass delamination is the shedding of thin glass flakes from the interior surface of vials into the drug product. It is driven by chemical attack from the formulation and can contaminate the product with glass particles, posing a direct safety risk to patients. High-pH formulations and certain biologics are most at risk.
What is the difference between Type I, II, and III glass for parenterals? Type I (borosilicate) has the highest hydrolytic resistance and is used for most parenterals. Type II (soda-lime, surface-treated) is used for aqueous preparations with limited pH ranges. Type III (soda-lime, untreated) is generally not used for aqueous injectables.
What extractables are of greatest concern in rubber stoppers? Key concerns include N-nitrosamines (potent carcinogens), 2-mercaptobenzothiazole (MBT, a vulcanization accelerator), antioxidants (Irganox, Tinuvin series), and zinc compounds. Modern bromobutyl and chlorobutyl stoppers have improved extractables profiles compared to natural rubber.
When must a full E&L study be performed for a parenteral product? A full E&L study is required for all new parenteral drug applications, significant packaging changes, new drug formulations using existing packaging, and when extractables screening identifies compounds above the analytical evaluation threshold.
What is the sub-visible particulate limit for parenteral injectables? USP <788> limits for LVPs (≥100 mL): not more than 25 particles/mL ≥10 µm and not more than 3 particles/mL ≥25 µm. SVPs (<100 mL): not more than 6,000 particles/container ≥10 µm and not more than 600 particles/container ≥25 µm.
